Targeting the ERβ/HER oncogenic network in lung cancer: synergistic antitumor interaction and potentiation of anti-PD1 efficacy
AA Almotlak - 2020 - search.proquest.com
Lung cancer is the leading cause of cancer related mortality in the United States, accounting
for more than 142,000 estimated deaths in 2019. The major subtype of lung cancer is non …
for more than 142,000 estimated deaths in 2019. The major subtype of lung cancer is non …
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
E Cusano, C Wong, E Taguedong, M Vaska, T Abedin… - Current …, 2021 - mdpi.com
In the era of rapid development of new, expensive cancer therapies, value frameworks have
been developed to quantify clinical benefit (CB). We assessed the evolution of CB since the …
been developed to quantify clinical benefit (CB). We assessed the evolution of CB since the …
[HTML][HTML] Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer
ZA Yochum, LP Stabile - Translational Lung Cancer Research, 2020 - ncbi.nlm.nih.gov
Conversely, longitudinal data on women with ER+ breast cancers treated with anti-estrogen
therapies demonstrated that these patients had a decreased risk of developing lung cancer …
therapies demonstrated that these patients had a decreased risk of developing lung cancer …
[引用][C] دارو رسانی هدفمند ارلوتینیب با استفاده از نانوذرات مغناطیسی با واسطه آپتامر اختصاصی موسین۱۶
محقق, سراج - 2020 - دانشگاه علوم پزشکی تبریز، دانشکده …
[引用][C] Mucin-16 aptamer directed targeted delivery of Erlotinib using PEGylated magnetic nanoparticles
S Mohaghegh - 2020 - Tabriz University of Medical …